• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

李-佛美尼综合征中基因型-表型关联:德国注册处的报告。

Genotype-phenotype associations within the Li-Fraumeni spectrum: a report from the German Registry.

机构信息

Pediatric Hematology and Oncology, Hannover Medical School, Carl-Neuberg Str. 1, 30625, Hannover, Germany.

Department of Human Genetics, Hannover Medical School, Hannover, Germany.

出版信息

J Hematol Oncol. 2022 Aug 16;15(1):107. doi: 10.1186/s13045-022-01332-1.

DOI:
10.1186/s13045-022-01332-1
PMID:35974385
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9382737/
Abstract

Li-Fraumeni syndrome (LFS) is a cancer predisposition syndrome caused by pathogenic TP53 variants. The condition represents one of the most relevant genetic causes of cancer in children and adults due to its frequency and high cancer risk. The term Li-Fraumeni spectrum reflects the evolving phenotypic variability of the condition. Within this spectrum, patients who meet specific LFS criteria are diagnosed with LFS, while patients who do not meet these criteria are diagnosed with attenuated LFS. To explore genotype-phenotype correlations we analyzed 141 individuals from 94 families with pathogenic TP53 variants registered in the German Cancer Predisposition Syndrome Registry. Twenty-one (22%) families had attenuated LFS and 73 (78%) families met the criteria of LFS. NULL variants occurred in 32 (44%) families with LFS and in two (9.5%) families with attenuated LFS (P value < 0.01). Kato partially functional variants were present in 10 out of 53 (19%) families without childhood cancer except adrenocortical carcinoma (ACC) versus 0 out of 41 families with childhood cancer other than ACC alone (P value < 0.01). Our study suggests genotype-phenotype correlations encouraging further analyses.

摘要

李-佛美尼综合征(Li-Fraumeni syndrome,LFS)是一种由致病性 TP53 变异引起的癌症易感性综合征。由于其频率和高癌症风险,该病症是儿童和成人中最重要的遗传致癌原因之一。Li-Fraumeni 谱这一术语反映了该病症表型可变性的演变。在此谱中,符合特定 LFS 标准的患者被诊断为 LFS,而不符合这些标准的患者则被诊断为 LFS 衰减型。为了探讨基因型-表型相关性,我们分析了在德国癌症易感性综合征登记处登记的 94 个携带有致病性 TP53 变异的家庭中的 141 名个体。21 个(22%)家庭为 LFS 衰减型,73 个(78%)家庭符合 LFS 标准。在符合 LFS 标准的家庭中,32 个(44%)存在 NULL 变异,在符合 LFS 衰减型标准的家庭中,2 个(9.5%)存在 NULL 变异(P 值<0.01)。在没有儿童癌症(除肾上腺皮质癌外)的 53 个家庭中,有 10 个存在部分功能 Kato 变异,而在除了儿童癌症(除肾上腺皮质癌外)之外的 41 个家庭中,没有一个存在这种变异(P 值<0.01)。我们的研究表明,基因型-表型相关性存在,鼓励进一步分析。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7076/9382737/e831c588e57f/13045_2022_1332_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7076/9382737/e4055862bff5/13045_2022_1332_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7076/9382737/e831c588e57f/13045_2022_1332_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7076/9382737/e4055862bff5/13045_2022_1332_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7076/9382737/e831c588e57f/13045_2022_1332_Fig2_HTML.jpg

相似文献

1
Genotype-phenotype associations within the Li-Fraumeni spectrum: a report from the German Registry.李-佛美尼综合征中基因型-表型关联:德国注册处的报告。
J Hematol Oncol. 2022 Aug 16;15(1):107. doi: 10.1186/s13045-022-01332-1.
2
Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil.巴西南部儿童癌症患者中李-佛美尼综合征和李-佛美尼样综合征。
Cancer. 2013 Dec 15;119(24):4341-9. doi: 10.1002/cncr.28346. Epub 2013 Oct 7.
3
Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set: An International Agency for Research on Cancer TP53 Database Analysis.基于国际胚系 TP53 变异数据集中的 Li-Fraumeni 谱分析:国际癌症研究机构 TP53 数据库分析。
JAMA Oncol. 2021 Dec 1;7(12):1800-1805. doi: 10.1001/jamaoncol.2021.4398.
4
Clinical spectrum of Li-Fraumeni syndrome/Li-Fraumeni-like syndrome in Brazilian individuals with the TP53 p.R337H mutation.巴西个体中 TP53 p.R337H 突变的 Li-Fraumeni 综合征/Li-Fraumeni 样综合征的临床谱。
J Steroid Biochem Mol Biol. 2019 Jun;190:250-255. doi: 10.1016/j.jsbmb.2019.04.011. Epub 2019 Apr 8.
5
Li-Fraumeni syndrome in Tunisian carriers with different and rare tumor phenotype: genotype-phenotype correlation.Li-Fraumeni 综合征在具有不同和罕见肿瘤表型的突尼斯携带者中的表现:基因型-表型相关性。
BMC Med Genomics. 2022 Mar 4;15(1):44. doi: 10.1186/s12920-022-01189-w.
6
TP53 and CDKN1A mutation analysis in families with Li-Fraumeni and Li-Fraumeni like syndromes.李-佛美尼综合征及类李-佛美尼综合征家族中的TP53和CDKN1A突变分析
Fam Cancer. 2017 Apr;16(2):243-248. doi: 10.1007/s10689-016-9935-z.
7
TP53 germline mutations in adult patients with adrenocortical carcinoma.成人肾上腺皮质癌中 TP53 种系突变。
J Clin Endocrinol Metab. 2012 Mar;97(3):E476-85. doi: 10.1210/jc.2011-1982. Epub 2011 Dec 14.
8
TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.180 个疑似李-佛美尼综合征家族的 TP53 种系突变检测:不同家族表型中癌症的突变检出率和相对频率。
J Med Genet. 2010 Jun;47(6):421-8. doi: 10.1136/jmg.2009.073429.
9
Report of 2 Pediatric Cases With Li-Fraumeni Syndrome Related Malignancy in a Family.一个家族中两例与李-弗劳梅尼综合征相关恶性肿瘤的儿科病例报告。
J Pediatr Hematol Oncol. 2021 May 1;43(4):e567-e570. doi: 10.1097/MPH.0000000000001862.
10
Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort.美国国立癌症研究所李-弗劳梅尼综合征队列中TP53突变携带者首次患癌及后续患癌风险
Cancer. 2016 Dec 1;122(23):3673-3681. doi: 10.1002/cncr.30248. Epub 2016 Aug 6.

引用本文的文献

1
In-frame germline TP53 variant impairs p53 oligomerization and predisposes to cancer.框内种系TP53变异会损害p53寡聚化并易患癌症。
Sci Rep. 2025 Aug 19;15(1):30459. doi: 10.1038/s41598-025-14684-8.
2
Model of care for individuals with rare cancer predisposition syndromes in Germany.德国罕见癌症易感性综合征患者的护理模式。
Lancet Reg Health Eur. 2025 Jun 26;56:101358. doi: 10.1016/j.lanepe.2025.101358. eCollection 2025 Sep.
3
Germline TP53 p.R337H and XAF1 p.E134* Variants: Prevalence in Paraguay and Comparison with Rates in Brazilian State of Paraná and Previous Findings at the Paraguayan-Brazilian Border.

本文引用的文献

1
Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set: An International Agency for Research on Cancer TP53 Database Analysis.基于国际胚系 TP53 变异数据集中的 Li-Fraumeni 谱分析:国际癌症研究机构 TP53 数据库分析。
JAMA Oncol. 2021 Dec 1;7(12):1800-1805. doi: 10.1001/jamaoncol.2021.4398.
2
Specifications of the ACMG/AMP variant interpretation guidelines for germline TP53 variants.ACMG/AMP 种系 TP53 变异解读指南的规范。
Hum Mutat. 2021 Mar;42(3):223-236. doi: 10.1002/humu.24152. Epub 2020 Dec 25.
3
Genotype-phenotype correlations among TP53 carriers: Literature review and analysis of probands undergoing multi-gene panel testing and single-gene testing.
种系TP53 p.R337H和XAF1 p.E134*变异:巴拉圭的患病率及其与巴西巴拉那州患病率的比较以及巴拉圭-巴西边境地区既往研究结果对比
Curr Oncol. 2025 Jun 6;32(6):333. doi: 10.3390/curroncol32060333.
4
Cancer risk in carriers of TP53 germline variants grouped into different functional categories.TP53种系变异携带者按不同功能类别分组后的癌症风险。
JNCI Cancer Spectr. 2025 Jan 3;9(1). doi: 10.1093/jncics/pkaf008.
5
Case review of perivascular epithelioid cell tumor occurring in patients with Li-Fraumeni syndrome.李-弗劳梅尼综合征患者发生血管周上皮样细胞肿瘤的病例回顾
Fam Cancer. 2025 Jan 24;24(1):18. doi: 10.1007/s10689-025-00442-2.
6
Clustering of variants into functional classes correlates with cancer risk and identifies different phenotypes of Li-Fraumeni syndrome.将变异聚类到功能类别与癌症风险相关,并可识别李-佛美尼综合征的不同表型。
iScience. 2024 Nov 1;27(12):111296. doi: 10.1016/j.isci.2024.111296. eCollection 2024 Dec 20.
7
Re-envisioning genetic predisposition to childhood and adolescent cancers.重新审视儿童和青少年癌症的遗传易感性。
Nat Rev Cancer. 2025 Feb;25(2):109-128. doi: 10.1038/s41568-024-00775-7. Epub 2024 Dec 3.
8
Current insights and future directions of Li-Fraumeni syndrome.李-弗劳梅尼综合征的当前见解与未来方向
Discov Oncol. 2024 Oct 15;15(1):561. doi: 10.1007/s12672-024-01435-w.
9
Cell-free DNA from germline TP53 mutation carriers reflect cancer-like fragmentation patterns.胚系 TP53 突变携带者的无细胞 DNA 反映出类似癌症的碎片化模式。
Nat Commun. 2024 Aug 27;15(1):7386. doi: 10.1038/s41467-024-51529-w.
10
TP53-associated early breast cancer: new observations from a large cohort.TP53 相关早期乳腺癌:大型队列的新观察。
J Natl Cancer Inst. 2024 Aug 1;116(8):1246-1254. doi: 10.1093/jnci/djae074.
TP53基因携带者的基因型-表型相关性:文献综述以及对接受多基因检测和单基因检测的先证者的分析
Cancer Genet. 2020 Oct;248-249:11-17. doi: 10.1016/j.cancergen.2020.09.002. Epub 2020 Sep 11.
4
Genotype-phenotype associations among panel-based TP53+ subjects.基于 panel 的 TP53+ 受试者的基因型-表型关联。
Genet Med. 2019 Nov;21(11):2478-2484. doi: 10.1038/s41436-019-0541-y. Epub 2019 May 20.
5
Mutational processes shape the landscape of TP53 mutations in human cancer.突变过程塑造了人类癌症中 TP53 突变的景观。
Nat Genet. 2018 Oct;50(10):1381-1387. doi: 10.1038/s41588-018-0204-y. Epub 2018 Sep 17.
6
A Systematic p53 Mutation Library Links Differential Functional Impact to Cancer Mutation Pattern and Evolutionary Conservation.一个系统性的p53突变文库将不同的功能影响与癌症突变模式及进化保守性联系起来。
Mol Cell. 2018 Sep 6;71(5):873. doi: 10.1016/j.molcel.2018.08.013.
7
Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers.重新审视携 TP53 突变者的李-佛美尼综合征。
J Clin Oncol. 2015 Jul 20;33(21):2345-52. doi: 10.1200/JCO.2014.59.5728. Epub 2015 May 26.
8
Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes.胚系携带突变型 TP53 的显性负性特征对癌症结局的影响有限。
Mol Cancer Res. 2011 Mar;9(3):271-9. doi: 10.1158/1541-7786.MCR-10-0496. Epub 2011 Feb 22.
9
Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers.缺乏显性野生型p53抑制作用的无活性全长p53突变体突出了杂合性缺失作为人类癌症中p53状态的一个重要方面。
Carcinogenesis. 2007 Feb;28(2):289-98. doi: 10.1093/carcin/bgl132. Epub 2006 Jul 21.
10
Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis.通过高分辨率错义突变分析理解p53肿瘤抑制蛋白的功能-结构和功能-突变关系。
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8424-9. doi: 10.1073/pnas.1431692100. Epub 2003 Jun 25.